Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pro-apoptotic and cell cycle-modulating effects of lobaric and rhizocarpic acids in human leukemic cell lines.

Molecular biology reports·2026
Same author

To Calculate the Nationwide Incidence/Prevalence Figures for Charcot-Marie-Tooth Disease, the Entire Population Must be Screened.

Neurosciences (Riyadh, Saudi Arabia)·2026
Same author

Leveraging the antibacterial and antibiofilm activities of Cymbopogon flexuosus essential oil against multidrug-resistant bacteria recovered from avian colibacillosis and bovine mastitis: in vitro and molecular docking insights.

Veterinary research communications·2026
Same author

<i>OncoSolidDB</i>: An Oncology-Focused Curated Database of Ligand-Target Interactions for Precision Medicine Across Major Solid Cancers.

Cancers·2026
Same author

Tenascin-C orchestrates radiotherapy-induced head and neck tumor regression.

EMBO molecular medicine·2026
Same author

Whole genome investigation of multi-drug resistant Staphylococcus aureus strain.

World journal of microbiology & biotechnology·2026

Related Experiment Video

Updated: Mar 29, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K

A High-Affinity Nanobody Selectively Recognizing KPC-2/KPC-3: Biochemical and Structural Insights.

Emna Hamdi1,2, Oussema Khamessi3,4, Alessandra Piccirilli2

  • 1Laboratoire Des Biomolécules, Venins et Applications Théranostiques, Institut Pasteur Tunis, Université Tunis El Manar, B.PN°93, 13 Place Pasteur, Tunis 1002, Tunisia.

Biomolecules
|March 28, 2026
PubMed
Summary

Researchers developed a novel nanobody targeting KPC-3, a carbapenemase enzyme. This nanobody effectively detects KPC-2 and KPC-3 variants in bacteria, offering a new tool for infection control.

Keywords:
KPC-2KPC-3carbapenem resistancenanobodies (VHHs)β-lactamase detectionβ-lactamases

More Related Videos

Antibody Binding Specificity for Kappa (V&#954;) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.6K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

21.6K

Related Experiment Videos

Last Updated: Mar 29, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K
Antibody Binding Specificity for Kappa (V&#954;) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.6K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

21.6K

Area of Science:

  • Microbiology
  • Biotechnology
  • Immunology

Background:

  • Carbapenemase-producing Enterobacteriaceae (CPE) are a major global health concern, driven by resistance to last-resort antibiotics.
  • The KPC-3 variant is a prevalent carbapenemase, necessitating rapid detection methods for effective clinical management.
  • Conventional antibodies face limitations in stability and epitope access, highlighting the need for alternative detection tools.

Purpose of the Study:

  • To generate and characterize a nanobody (VHH) with high specificity for the KPC-3 carbapenemase.
  • To evaluate the nanobody's potential as a diagnostic tool for detecting KPC-producing bacteria.
  • To explore the nanobody's binding characteristics and potential for future therapeutic applications.

Main Methods:

  • Construction and screening of an immune VHH phage display library against KPC-3.
  • Validation of nanobody binding using ELISA and Western blot assays.
  • Analysis of nanobody recognition of KPC variants in bacterial periplasmic extracts and structural modeling.

Main Results:

  • A nanobody targeting KPC-3 was successfully generated and validated.
  • The nanobody demonstrated high binding affinity for both KPC-2 and KPC-3 variants.
  • Structural modeling indicated favorable interaction surfaces for nanobody binding.

Conclusions:

  • This study presents the first nanobody targeting KPC-3, capable of recognizing a conserved epitope shared by KPC-2 and KPC-3.
  • The developed nanobody shows significant promise as a molecular tool for detecting KPC variants in clinical settings.
  • Further affinity maturation of this nanobody could lead to novel therapeutic strategies against carbapenemase-producing bacteria.